LON:SUMM Summit Therapeutics (SUMM) Share Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free SUMM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 20.50▼ 20.5052-Week Range N/AVolume280,318 shsAverage Volume382,504 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Summit Therapeutics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Summit Therapeutics Stock (LON:SUMM)Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. SUMM Stock News HeadlinesMay 2, 2024 | seekingalpha.comSummit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comQ1 2024 Summit Therapeutics Inc Earnings CallMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. April 30, 2024 | bizjournals.comRxLightning, BehaVR founders reflect on becoming CEOsApril 29, 2024 | afr.com‘The right time to go’: Maskell to leave Melbourne UniversityApril 27, 2024 | msn.comHunt calls Dorneywood summit to boost flagging UK stock marketApril 23, 2024 | markets.businessinsider.comAspen Ideas: Health Announces Global Health Experts to Speak at Annual SummitApril 18, 2024 | finance.yahoo.comRenibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation SummitMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 16, 2024 | finance.yahoo.com2024 DTA Summit Agenda is LIVE!!April 13, 2024 | investing.comSummit Therapeutics appoints genomics expert to boardApril 9, 2024 | msn.comIllumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeedApril 8, 2024 | msn.comCarisma Therapeutics to Present at Upcoming Healthcare ConferencesApril 5, 2024 | finance.yahoo.comIn coordination with DoH J.P. Morgan's Life Sciences Private Capital announces Life Sciences Innovation Summit 2024 finalists ahead of ADGHWApril 4, 2024 | finance.yahoo.comNorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation SummitApril 2, 2024 | msn.comFrance’s Superprod Group Acquires Luxembourg Animation Duo Studio 352 & Mélusine ProductionsApril 2, 2024 | finance.yahoo.comSpotlighting Excellence: Keiretsu Forum Curates Premiere Investment Opportunities for the 2024 Angel Capital Association Innovation Funders ShowcaseMarch 29, 2024 | msn.comWhy Summit Therapeutics Stock Crushed the Market This WeekMarch 28, 2024 | benzinga.comAkeso Marks Profit Milestone With Swift Rights IssueMarch 27, 2024 | finance.yahoo.comCoave Therapeutics to Present at Upcoming ConferencesMarch 27, 2024 | msn.comLukashenko says concert hall attackers first headed for Belarus, contradicting PutinMarch 27, 2024 | msn.comPolice probe possible bomb threat at Simi Valley surgery centerMarch 27, 2024 | markets.businessinsider.comAnalysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer TreatmentMarch 26, 2024 | finanznachrichten.deEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023March 26, 2024 | seekingalpha.comWall Street Breakfast Podcast: Lucid Group Secures $1B InvestmentMarch 25, 2024 | finance.yahoo.comSummit Therapeutics Insiders Up US$5.1m On US$5.05m InvestmentMarch 22, 2024 | stockhouse.comPromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024See More Headlines Receive SUMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/12/2019Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drugs - Generic Sub-IndustryN/A Current SymbolLON:SUMM CUSIPN/A CIKN/A Webwww.summitplc.com Phone+44-1235-443939FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Glyn O. Edwards (Age 63)CEO & Exec. Director Mr. Erik Ostrowski (Age 46)Chief Financial Officer Prof. David Roblin (Age 53)COO, Chief Medical Officer and Pres of R&D Prof. Kay Davies (Age 69)Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Michelle AveryDirector of Investor RelationsKey CompetitorsAbzenaLON:ABZAAPR EnergyLON:APRCambian GroupLON:CMBNPremaitha HealthLON:NIPTSinclair PharmaLON:SPHView All Competitors SUMM Stock Analysis - Frequently Asked Questions How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (LON:SUMM) announced its earnings results on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.00) by $1.00. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF). How do I buy shares of Summit Therapeutics? Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SUMM) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
